Tue, Jul-19-16, 18:34
|
 |
Senior Member
Posts: 3,199
|
|
Plan: High protein, lower fat
Stats: 000/000/145
BF:276, 255 hi wts
Progress: 0%
Location: Michigan U.P., USA
|
|
Yikes is right. Meanwhile...
No Clear Survival Benefit Seen Among Diabetes Drugs - But meta-analysis hampered by limitations of included studies
Eight different diabetes drug classes examined in a meta-analysis failed to demonstrate improved cardiovascular or all-cause mortality compared with placebo.
http://www.medpagetoday.com/endocri.../diabetes/59182
Also:
Quote:
The analysis of hundreds of clinical trials found no evidence that any one diabetes drug, or drug combination, beats out the others.
Researchers said the results bolster current recommendations to first try an older, cheaper drug -- metformin (Glumetza, Glucophage) -- for most patients with type 2 diabetes.
"There are very few things experts agree on, but this is one of them," said Dr. Kevin Pantalone, a diabetes specialist at the Cleveland Clinic and a member of the Endocrine Society.
http://health.usnews.com/health-car...es-drug-is-best
|
Quote:
Meta-analysis Supports ADA Guidelines for Type 2 Diabetes Drugs
In a systemic review and network meta-analysis, the available drugs classes for type 2 diabetes were associated with similar odds of cardiovascular and all-cause mortality. Patients receiving metformin monotherapy had lower or similar HbA1c levels as those receiving sulfonylurea, thiazolidinedione, or α-glucosidase inhibitor monotherapy. http://www.medscape.com/viewarticle/866322
|
The gastrointestinal side effects preventing some patients from using Metformin were mentioned. I really wonder if that reflects the state of their guts.
|